IGF‑1 LR3 (1 mg) is a synthetic peptide analog of insulin‑like growth factor‑1 (IGF‑1), modified by the addition of an extended amino acid sequence and substitution at the third position (Arg3). This structural modification distinguishes it from native IGF‑1 and alters its interactions with cellular signaling pathways compared with the endogenous growth factor. The peptide consists of an extended chain relative to endogenous IGF‑1 and is commonly referred to as Long R3‑IGF‑1 in research literature.

IGF‑1 LR3 has been studied in experimental models exploring cellular growth signaling, metabolic regulation, and intracellular communication pathways. It is used in laboratory settings to investigate how growth factor analogs interact with receptors and downstream signaling cascades involved in cell proliferation, differentiation, and protein synthesis. It is supplied as a lyophilized powder in a sealed research‑grade vial for controlled laboratory use.

IGF-1 LR3 (1mg) Key Features & Specs

• Subcategory: Growth Factor & Metabolic Research Peptides
• Strength: 1 mg
• CAS: 946870-92-4
• Chemical Formula: C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
• Molecular Weight:60 g/mol
• Peptide Sequence: MFPAMPLSSL–FVNGPRTLCG–AYGGSCASFR–RGFYFNKPTG–YGSSTKKAYG–NNYRRHPLLK–PPIKSAQG
• Synonyms: Long R3-IGF-1, M9L22Y19H9, 143045-27-6, Long-(arg3)insulin-like growth factor-i, IGF-I analog

For laboratory research use only.

IGF-1 LR3 (1mg) Research Uses

IGF-1 LR3 (1mg) has been studied in laboratory environments focused on cellular growth signaling and metabolic regulation. As an analog of IGF-1, it is commonly used in research examining pathways involved in cell proliferation, differentiation, and protein synthesis.

Research involving this peptide often explores biological systems such as muscle cell signaling, metabolic activity, and intracellular communication pathways. These studies aim to understand how growth factor analogs may influence cellular processes related to growth and energy regulation.

In experimental models, IGF-1 LR3 is used to investigate how signaling molecules interact with cellular systems that regulate growth-related pathways and metabolic balance.

IGF-1 LR3 (1mg) Insights & Observed Findings

Preclinical and in vitro studies involving IGF-1 analogs have evaluated peptide activity across nanomolar concentration ranges, depending on the experimental design and biological system. These studies are typically conducted in controlled laboratory settings to examine cellular signaling responses.

Animal studies investigating growth factor peptides have reported dosing ranges in the microgram-per-kilogram (µg/kg) range. Experimental parameters vary based on the research objective and the signaling pathways being analyzed.

Observed findings suggest that IGF-1 analogs may influence molecular pathways involved in cellular growth, protein synthesis, and metabolic signaling. These findings remain under investigation and should not be interpreted as evidence of clinical outcomes.

IGF-1 LR3 (1mg) Handling & Storage

• Store under controlled laboratory conditions
• Refrigeration at 2–8 °C is recommended; –20 °C may be used for storage in research environments
• Protect the lyophilized powder from light, heat, and moisture
• After reconstitution with sterile laboratory-grade solvent, store the solution at 2–8 °C and handle according to standard laboratory protocols
• Avoid repeated freeze–thaw cycles, as these may affect peptide stability
• Use appropriate laboratory protective equipment during handling and follow institutional biosafety guidelines for handling and disposal

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Bailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules. 2021;11(2):217. Published 2021 Feb 4. doi:10.3390/biom11020217
2. Bach LA, Hsieh S, Sakano K, Fujiwara H, Perdue JF, Rechler MM. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. J Biol Chem. 1993;268(13):9246-9254.
3. Abellan R, Ventura R, Palmi I, et al. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes. J Pharm Biomed Anal. 2008;48(3):844-852. doi:10.1016/j.jpba.2008.05.037